Serum-starvation induces the extracellular appearance of FGF-1  by Shin, Jordan T. et al.
et Biophysics &ta 
ELSEVIER Biochimica et Biophysics Acta 1312 (1996) 27-38 
Serum-starvation induces the extracellular appearance of FGF- 1 
Jordan T. Shin a, Susan R. Opalenik a, John N. Wehby a, Vinit K. Mahesh a, 
Anthony Jackson b, Francesca Tarantini b, Thomas Maciag b, John A. Thompson a3 *
a Division of Transplantation, Department of Surgery, School of Medicine, Universie of Alabama at Birmingham, UAB Station, Birmingham, AL 35294, 
USA 
b Department of Molecular Biology, Holland Laboratory, American Red Cross, I5601 Crabbs Branch Way, Rockcille, MD 20855, USA 
Received 13 September 1995; accepted 5 January 1996 
Abstract 
Autoctine/paracrine stimulation of cell growth by members of the fibroblast growth factor (FGF) family of polypeptides is dependent 
upon extracellular interactions with specific high affinity receptors at the cell surface. Acidic FGF (FGF-1) lacks a classical signal 
sequence for secretion, suggesting that intrinsic levels of this mitogen may not stimulate cell growth and utilizes a non-classical pathway 
to gain access to the extracellular compartment. To evaluate the biological potential of intracellular FGF-1 more rigorously, human cDNA 
sequences for the growth factor were introduced into primary murine embryonic fibroblasts using retrovirally mediated gene transfer. 
Heparin affinity, Western analysis, mitogenic assays, in situ immunohistochemical techniques, induction of tyrosine phosphotylation and 
antibody inhibition studies were used to demonstrate functionality of the FGF-1 transgene in this experimental model. Under normal 
culture conditions, cells constitutively expressing intracellular FGF-1 exhibited a slight growth advantage. In contrast, when maintained in 
reduced serum, these cells adopted a transformed phenotype and demonstrated an enhanced growth potential, induction of FGF-specific 
phosphotyrosyl proteins and the nuclear association of the growth factor. Analysis of the conditioned media from these stressed cells 
indicated that serum starvation induces the secretion of FGF-1 as latent high molecular mass complexes requiring reducing agents to 
activate its full biological potential. 
Keywords: Serum starvation; Fibroblast growth factor; Biological potential; Primary murine embryonic fibroblast; cDNA sequence 
1. Introduction 
The prototype members of the fibroblast growth factor 
(FGF) gene family are well-recognized as initiators of 
angiogenesis [1,2]. All members of the FGF family share a 
high degree of sequence similarity at both the nucleotide 
and amino acid level and have in common several struc- 
tural motifs. Six members of the human FGF gene family, 
including FGF-3 (int-21, FGF-4 (hst/KS), FGF-5, FGF-6 
(hst-2), FGF-7 (KGF) and FGF-8 (AIGF), each contain an 
Abbreviations: FGF, fibroblast growth factor; FGF-1, acidic FGF; 
P-gal, P-galactosidase; DMEM, Dulbecco’s modified Eagle’s medium; 
FBS, fetal bovine serum; PBS, phosphate-buffered saline; PCR, poly- 
merase chain reaction; RT-PCR, reverse transcriptase-PCR; HRP, 
horseradish peroxidase; BrdU, bromodeoxyuridine; DAB, 3,3’-diamino- 
benzidine; FACS, fluorescence-activated cell sorting; SDS-PAGE, sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis; D’lT, dithiothreitol. 
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amino terminal secretory signal sequence [3-101 suggest- 
ing that autocrine stimulation of cell proliferation by these 
growth factors requires an extracellular pathway 13-131. 
However, FGF-9 (GAF), which does not contain an appar- 
ent classical signal sequence, has been shown to be re- 
leased from cells in vitro [14]. With the exception of 
FGF-7 and FGF-9, this structural feature correlates with 
the classification of these FGFs as oncoproteins based on 
their characteristic transforming potential [2]. 
FGF-1 (acidic) and FGF-2 (basic) are unusual in that, 
unlike the FGF oncogenes, they lack a classical signal 
sequence for secretion. This structural feature has made it 
difficult to evaluate regulation of biological activity by 
these prototypes. Previous attempts to evaluate the mito- 
genie potential of FGF-1 and FGF-2 have involved forced 
secretion of these polypeptides. Transfection [ 12,15-201 
and transduction [21] studies with FGF chimeras contain- 
ing various signal sequences have described the ability of 
secreted FGF-1 and FGF-2 to mediate cellular transforma- 
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tion. Collectively, these and other studies have established 
that, as extracellular proteins, the biological activity of the 
FGF prototypes involves productive interactions with a 
receptor complex on the cell surface [22-241 followed by 
activation of intrinsic tyrosine kinase [22,23], phosphoryla- 
tion of specific polypeptides 1221, nuclear translocation of 
the ligand [25,26], and association of the high affinity 
receptor (FGFR-1) with the nuclear compartment as a 
struturally intact and functional tyrosine kinase [27]. 
Previous studies have demonstrated aberrant phenotypic 
appearance and growth behavior in vitro of cell lines 
transfected with intrinsic FGF-1 [18-201. However, these 
results would seem inconsistent with the fact that prolifera- 
tion mediated by these widely produced and distributed 
prototypic growth factors is not observed physiologically, 
even in those tissues where the concentration of FGF is 
highest 121. This suggests that under normal conditions, 
intracellularly sequestered FGF may not be available to 
mediate its biological effects on cell growth and differenti- 
ation. Consequently, mechanisms whereby the cytosolic 
growth factors are released into the extracellular environ- 
ment become fundamental for understanding regulation of 
FGF biology. 
In the absence of defined mechanisms regulating the 
release of the FGF prototypes from intracellular stores, 
most studies have proposed that the extracellular appear- 
ance of FGF-1 and FGF-2 are the consequence of cell 
death or damage [28-301. However, previous results have 
determined that FGF-2 can be released from cytoplasmic 
stores by an exocytosis pathway independent of the endo- 
plasmic reticulum (ERl-Golgi apparatus [3 11. In addition, 
FGF-1 has been demonstrated to be released from NIH 
3T3 cells in response to heat shock [32] by an ER-indepen- 
dent pathway as a latent complex, which requires activa- 
tion by reducing agents [33]. More recent efforts [21] have 
suggested that FGF-1 is secreted from cells as a latent, 
high molecular mass complex in response to oxidative 
stress. Since hyperthermic, oxidative stress, and serum- 
starvation responses overlap [34-371, the role of serum- 
starvation as a mechanism for inducing the secretion of 
FGF-1 was examined in vitro. We report that primary 
embryonic murine fibroblasts, transduced with a single 
copy of the human FGF-1 gene, are able to release this 
growth factor in response to serum deprivation. In addi- 
tion, several lines of evidence suggest that an inverse 
relationship exists between serum concentration and secre- 
tion of FGF- 1, which appears in the extracellular compart- 
ment as large molecular mass, non-covalent complexes. 
2. Materials and methods 
2.1. Vector construction 
To generate specific retroviral constructs (Fig. l), the 
prokaryotic 1acZ gene encoding P-galactosidase ( p-gal> 
Bg i&l+ 
L Bg S F L 
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Fig. 1. Structure of the retroviral vectors. Both of the retroviral vector 
constructs contains a 5’.LTR (L) directing expression of P-galactosidase 
(Bg). The experimental vector includes the human FGF-1 cDNA se- 
quence (F) cloned under control of the early SV40 promoter 6). The 
untranslated leader sequence contains both a ribosome binding site (open 
box) and Kozak consensus sequence (hatched box) to maximize expres- 
sion of the growth factor. 
was cloned into pLNSX [38] following removal of the 
neomycin phosphotransferase (NPT) gene (Bg). Construc- 
tion of the synthetic, truncated human FGF-1 gene (amino 
acids 2 1 - 154) has been described and demonstrated to 
express active recombinant protein in prokaryotic systems 
1391. The open-reading frame (ORF) for FGF- 1 was cloned 
3’ of the early SV40 promoter (F) using a synthetic 
(Applied Biosystems, 380B) linker (27 bp), gatctttc- 
cgcagcagccgcccaccATG, which contained sequences for 
both an untranslated leader (lower case) and an ORF 
(upper case) that was fused in-frame to the NH,-terminus 
(ANYKK-1 of FGF-1. The untranslated leader (lower 
case) of the linker included potential ribosome binding 
(bold lettering) and Kozak (underlined) sequences for max- 
imal eukaryotic translational efficiency [40-421. Final 
retroviral constructs were propogated in Escherichia coZi 
(DH5a) and sequenced to confirm both identity and accu- 
racy of subcloning. 
The helper-free packaging cell line GP + envAm 12 [43] 
was cotransfected with either Bg or F together with 
pCV108, a vector containing the early SV40 promoter 
directing NPT expression (10: 1 molar ratio), using calcium 
phosphate-mediated precipitation [44]. Cells producing a 
high titer (106-lo7 CFU/ml) of amphotropic virus were 
isolated by P-gal expression using FACS [45] followed by 
selection (2 to 3 weeks) in 800 pg/ml G418 (Gibco). 
Viral titration was performed by determining the number 
of P-gal expressing colonies produced by transductions of 
3T3 cells [38] with serial dilutions of supematant from the 
producer line. Expression of P-gal was monitored enzy- 
matically [46] with the chromogenic substrate Bluo-gal 
(Gibco). 
2.2. Cell culture, transduction, and selection 
Primary murine fibroblasts were isolated from day 12 
C57/B6 embryos [47] and established in culture using 
DMEM (Gibco) supplemented with 10% (v/v) heat-in- 
activated FBS (Hyclone) and 100 units of penicillin and 
100 mg of streptomycin (Gibco). Population doublings 
were monitored and only early, stabilized passages were 
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used for these studies. Subconfluent (70-80%) fibroblasts 
were treated with retroviral particles (moi = 1 to 10) ob- 
tained from fresh (6 h) supernatant, conditioned by indi- 
vidual producer lines [21]. Transduced cells were isolated 
by FACS [45], plated (5 . lo3 cells/cm’), and expanded in 
culture for subsequent analyses. Resistance to growth in 
G418 (500 pg/ml) and lack of a detectable amplification 
product (PCR) for NPT [48] were used to confirm the 
absence of packaging cells in individual transduced popu- 
lations. Routine passage of isolated cells was performed at 
confluency following 0.05% (w/v) trypsin/OS M EDTA, 
treatment and replating (1 . lo4 cells/cm’). 
2.3. Growth analysis 
Transduced cells (1.5 . 104) were seeded in 12-well 
plates (Coming) previously coated with 3 pg/cm’ human 
plasma fibronectin (Gibco) and grown in DMEM supple- 
mented with either 10% (normal serum> or 0.5% 
(reduced-serum) FBS. Cells were washed (PBS) and fed 
every three days with fresh media. The number of viable 
cells (Trypan exclusion) for each transductant were counted 
by hemacytometer at specific time points, in duplicate, 
using 5 separate measurements per well. Lactate dehydro- 
genase (LDH) release assays were used to evaluate cell 
death/damage according to manufacturer’s specifications 
(Promega). For a more sensitive assessment of potential 
sublethal cell injury, cells were incubated (15 min, 20°C) 
with a mixture of fluorescein diacetate (FDA, 15 pg/ml) 
and propidium iodide (PI, 5 pg/ml) in Dulbecco’s-PBS as 
described [49]. Stained cells were observed immediately by 
epifluorescence microscopy (Microphot, Nikon) to quan- 
tify cell viability. Viable cells were identified by the 
green-yellow fluorescence resulting from hydrolysis of 
fluorescein diacetate by intracellular esterases. Injured cells 
were identified by the bright-red fluorescence resulting 
from the penetration and intercalation of propidium with 
DNA. The percentage of cell death was computed by 
assessing the ratio of red staining cells over the sum of red 
and green staining cells in at least 5 representative fields 
using a 10 X objective. 
2.4. Biochemical analysis 
Cells (1 . 104/cm2) were seeded and allowed to attach 
(16 h) under normal growth conditions. Cultures were 
washed (PBS) and fed DMEM, supplemented with indi- 
cated concentrations of FBS for defined periods of time. 
The simultaneous extraction of DNA and RNA was 
achieved and analyzed by PCR and RT-PCR techniques 
using previously established conditions [21]. To obtain 
extracellular proteins, conditioned media were harvested, 
centrifuged (2000 X g, 5 min) and filtered (0.45 p) to 
remove cellular debris. Total cellular and nuclear proteins 
were extracted from individual cell populations as de- 
scribed [21]. Total recovered proteins from individual cell 
populations and compartments were processed separately 
by affinity extraction using a heparin-Sepharose column 
[21,39] previously equilibrated in 20 mM Tris-HCl, pH 7.4 
containing 1 mM EDTA (TE) using an FPLC system 
(Pharmacia). Heparin-binding proteins were eluted (2.0 M 
NaCl in TE) and concentrated/desalted using the Centri- 
con-3 System (Amicon). 
2.5. SDS-PAGE and limited SDS-PAGE analysis 
Affinity-extracted proteins obtained from both total cel- 
lular and nuclear extracts were fractionated under reducing 
conditions using routine 15% (w/v) SDS-PAGE [21]. 
However, total heparin-binding proteins recovered from 
the conditioned media were resuspended in 62.5 mM 
Tris-HCl, pH 6.8, containing 5% (v/v) glycerol and 2% 
(w/v) SDS and immediately subjected to nonreducing 
15% (w/v) PAGE analysis under conditions in which 
neither the stacking and resolving gel, nor the running 
buffer contained SDS. Gels were transferred electrophoret- 
ically to PVDF membranes (Immobilon-P, Millipore) and 
incubated with an affinity purified antibody (1 pg/ml) 
against FGF- 1, which exhibits no cross-reactivity against 
FGF-2 and has served as a reagent useful for establishing 
the involvement of FGF-1 in inflammatory arthritic joints 
[50]. As a control for FGF-1 monospecificity, the affinity- 
purified anti-FGF-1 was preincubated (16 h, 4°C) with 
lOO-fold molar excess of recombinant FGF-1 [39], a pro- 
cess which completely blocked immunoblot staining. Re- 
combinant FGF-1 also served as a semi-quantitative im- 
munoreactive marker within the same gel for both SDS- 
PAGE and limited SDS-PAGE analysis. Membranes were 
probed with HRP conjugated goat anti-rabbit serum 
(Kirkegaard and Perry Labs, 1.33000) and treated with 
chemiluminescent substrates following manufacturer’s di- 
rections (Lumiglo, Kirkegaard and Perry Labs). Films 
were exposed to luminescent membranes and developed 
for varying amounts of time according to manufacturer’s 
specifications (X-OMAT. Kodak). 
2.6. Receptor-mediated tyrosine phosphorylation 
To evaluate endogenous levels of tyrosine phosphoryla- 
tion, cells were seeded (1 . 104/cm’) and allowed to at- 
tach (16 h) under normal growth conditions. Cultures were 
washed (PBS) and fed DMEM supplemented with either 
serum-free, hormonally defined media [20], normal (lo%, 
v/v) or reduced (0.5%, v/v) serum. After 72 h, cells were 
washed, extracted, immunoprecipitated, and analyzed [21] 
using polyclonal antibodies against either phosphotyrosine 
(1 pg/ml), cortactin (1:400) or c-src (1: 100, N- 16, Santa 
Cruz). To analyze paracrine stimulation, control (Bg)- 
transduced cells (1 . 106) were maintained (48 h) in 
serum-free, hormonally defined media [20]. Quiescent cells 
were washed (PBS) and fed (1 h, 37°C) 72-h conditioned 
media, which was obtained from individual cell popula- 
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tions maintained under defined culture conditions, Treated 
cells were washed, extracted, immunoprecipitated, and an- 
alyzed [21] using a polyclonal antibody against phospho- 
tyrosine (1 pg/ml). Where indicated, conditioned media 
included pretreatment with 1 mM DTT. Hormonally de- 
fined, serum-free media either with or without recombinant 
FGF-1 (50 ng/ml) and heparin (20 U/ml) served as 
positive and negative controls (respectively) for these stud- 
ies. 
2.7. In situ immunohistochemical analysis 
To measure the proliferation index (PI) of individual 
transductants, cells (1 . 104/cm2) were seeded and al- 
lowed to attach (16 h) under normal growth conditions. 
Cultures were washed (PBS) and fed DMEM, supple- 
mented with indicated concentrations of FBS for 68 h 
followed by labeling for 4 h with bromodeoxyuridine 
(BrdU, Sigma, 10 PM). Where indicated, culture media 
contained 30 pg/ml of an anti-FGF-1 polyclonal antibody 
(Sigma) added at 0, 24 and 48 h time points. To validate 
the mitogenic potential of the affinity-extracted FGF-1 
transgenes, NIH 3T3 cells (1 104/cm2) were seeded and 
allowed to attach (16 h) under normal growth conditions. 
Cultures were washed (PBS) and maintained (36 h) in 
0.5% (v/v) FBS. Either recombinant FGF- 1 or the FGF- 1 
transgenes, heparin-extracted from intra- and extracellular 
compartments, were added (20 h) in the presence of hep- 
arin (5 U/ml) to quiescent cells followed by labeling (4 h) 
with BrdU. Where indicated, recombinant FGF-1 and 
affinity-extracted transgenes were preincubated (16 h, 4°C) 
with 30 mg/ml polyclonal anti-FGF-1 antibody (Sigma) 
prior to addition. Activation of the high molecular mass 
FGF-1 complexes, extracted from the extracellular com- 
partment, was achieved by pretreatment with 1 mM DTT. 
Harvested cells were resuspended (lo5 cells/ml) and 0.1 
ml aliquots were centrifuged (Cytospin, Shandon-Lipshaw) 
onto glass microscope slides and immediately fixed, 
washed and analyzed as described [21]. Immunohistochem- 
ical localization of FGF-1 was performed using Vectastain 
Elite ABC following manufacturer’s recommendations 
(Vector Labs). Cells were centrifuged, fixed and depleted 
of endogenous peroxidase activity. Fixed cells were washed 
and incubated (30 min) with 1.5 pg/ml affinity-purified 
anti-FGF- 1 [50]. Primary murine fibroblasts transduced 
[21] with a retroviral vector engineered to direct expression 
of (hst/KS) FGF-1, a secreted, chimeric form of FGF-I, 
were used as a positive control. Negative controls included 
incubation of fixed cells with preimmune rabbit serum 
(10%) and deletion of the primary antibody. An additional 
control for FGF- 1 specificity included antibody blocking 
conditions as described for Western analyses, which com- 
pletely blocked cellular staining. Antibody-treated samples 
were incubated with biotinylated secondary antibody (goat, 
anti-rabbit) followed by avidin-biotin HRP (Vector ABC). 
Chromogenic development of stained samples permitted 
analysis via light microscopy. Nuclear-associated staining 
was determined by dividing DAB-stained nuclei by the 
total observed nuclei and statistical significance was as- 
sessed as described [21], using Student’s t-test (Abacus 
Concepts, Berkeley, CA). 
3. Results 
Primary cultures of embryonic murine fibroblasts were 
transduced independently with retroviral vectors (Fig. l), 
selected by FACS, and expanded for biochemical analyses. 
The transduction efficiency, as determined by percentage 
of cells expressing Bg (FACS), were approximately the 
same for each retroviral vector (30-35%). No attempt was 
made to subclone specific cell populations relative to 
expression levels of either the selectable marker (Bg) or 
modulatory transgene (FGF- 1). Characteristic PCR (DNA) 
and RT-PCR (RNA) products for Bg (355 bp) and the 
transduced FGF-1 (390 bp) were identified in expanded 
populations of individual cell transductants (data not 
shown). These results were consistent with the engineered 
retroviral nucleic acid sequences, thereby confirming both 
delivery of the nucleic acid sequences and the ability of 
primary murine fibroblasts to coordinate a transcriptional 
response from these templates. Similar levels of both Bg 
and FGF- 1 transgene mRNA were identified (RT-PCR) in 
individual cell transductants, regardless of culture condi- 
tions (10%. v/v, or 0.5%, v/v, FBS). Translation of Bg 
mRNA was confirmed on expanded populations of trans- 
duced cells using both analytical FACS and routine enzy- 
matic analyses. Greater than 98% of cells in each trans- 
duced population produced readily detectable levels of 
active Bg. 
When compared to Bg-transuced cells, cells constitu- 
tively expressing intrinsic FGF-1 exhibited a slight growth 
advantage under normal (1 O%, v/v, FBS) conditions (Fig. 
2A). When maintained in reduced serum (0.5%, v/v, 
FBS), Bg-transduced cells demonstrated minimal growth 
during the 12 days in culture. However, growth analysis of 
FGF- 1 -transduced cells demonstrated a similar initial qui- 
escent state for 6 days followed by a significantly in- 
creased proliferative potential (Fig. 2B). When maintained 
in reduced serum (0.5%, v/v, FBS), both Bg- and FGF-l- 
transduced cells released minimal levels of LDH into the 
extracellular compartment. Normalization of LDH units to 
total cell number determined that 1.94% of Bg-transduced 
cells experienced cell death/damage when maintained 72 
h in reduced serum. This value was reduced significantly 
(P < 0.01) to 1.37% in FGF-l-transduced cells. Assess- 
ment of FDA-PI staining following experimental condi- 
tions of serum deprivation determined that 3.17% of Bg- 
transduced cells demonstrated potential sublethal cell in- 
jury compared (P < 0.02) to 1.08% observed in FGF-l- 
transduced cells. Assessment of Trypan blue exclusion 
correlated well with both these assays and confirmed the 
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Fig. 2. Growth curves for individual transduced cell population. Primary 
murine fibroblasts were transduced, FACS-selected, and grown in dupli- 
cate as described (Section 2) in the presence of either 10% (v/v) (A) or 
0.5% (v/v) (B) FBS. The kinetics of growth behavior were determined 
for (@) Bg- and ( W ) FGF-l-transduced cells. Standard error bars for 
each data point are within the size of the individual symbols. 
absence of significant cell damage/death (< 2%) for ei- 
ther of the individual transductants throughout the time 
course of study. 
For a more detailed analytical evaluation, growth poten- 
tials were evaluated by determining the proliferation index 
(BrdU incorporation) of individual transduced cell popula- 
tions maintained (3 days) under defined culture conditions 
(Fig. 3A). The percentages of Bg- and FGF-l-transduced 
cells labeled under normal (lo%, v/v, FBS) conditions 
were very similar (40 and 43%, respectively) and did not 
demonstrate a significant statistical difference. Under 
Fig. 3. Proliferation index of individual transductants and mitogenic 
potential of FGF-1 transgenes: (A) Under growth arrest conditions (72 h; 
0.5%. v/v, FBS). the percentages of Bg- and FGF-l-transduced cells 
(1 lO’/cm’) labeled (BrdU incorporation, 4 h) were determined in the 
absence (0) or presence (M) of daily (24 h) additions of 30 pg/ml 
anti-FGF- 1 polyclonal antibody (Sigma). (B) Heparin Sepharose-ex- 
tracted recombinant FGF-1 (20 ng/ml) or FGF-1 transgenes (approx. 
lo- 15 ng/ml), recovered from either the intracellular or extracellular 
compartment of FGF-l-transduced cells maintained (72 h) in reduced 
(0.5% (v/v) FBS) or reduced (0.5% (v/v) FBS) serum, respectively, 
were analyzed for their ability to stimulate DNA synthesis in quiescent 
NIH 3T3 cells. Mitogenic activity (labeling index) was determined by 
BrdU incorporation in the absence (0 ) or presence ( n ) of 30 kg/ml 
polyclonal anti-FGF-1 antibody (Sigma). preincubated (16 h, 4°C) with 
the affinity-extracted FGF-1 transgene. Activation of the extracellular 
complex was achieved by pretreatment with 1 mM DTT prior to addition 
or preincubation with the antibody. 
growth arrest conditions (OS%, v/v, FBS), the labeling 
index of control-transduced cells (Bg) was reduced to 
2.6%. In contrast, FGF-l-transduced cells retained a high 
proliferation index (10.9%) in reduced serum that was 
significantly (P < 0.01) enhanced when compared to Bg- 
transduced cells. Daily additions (30 pg/ml) of poly- 
clonal antibody against FGF-1 under conditions of growth 
arrest (3 days; OS%, v/v, FBS) had no effect on Bg-trans- 
duced cells. In contrast, the polyclonal anti-FGF-1 signifi- 
cantly (P < 0.01) reduced the proliferation index (5.5%) of 
FGF- 1 -transduced cells maintained in reduced serum. 
Fig. 4. Phenotypic analysis of transduced cells maintained under defined culture conditions. Sub-confluent populations of Bg- (panel A) and FGF-l- 
(panels B and C) transduced cells were maintained (72 h) in either 10% (v/v) FBS (panels A and B) or 0.5% (v/v) FBS (panel C). The phenotypic 
appearance was examined by phase contrast microscopy (100 X magnification). 
32 J.T. Shin et al./Biochimica et Biophysics Acta 1312 (1996127-38 
The morphology of individual cell populations, seeded 
(1 . 104/cm2) and maintained (72 h) in normal serum 
(lo%, v/v, FBS) conditions, were observed microscopi- 
cally. Both Bg- and FGF- 1 -transduced cells displayed (Fig. 
4A and B) a typical monolayer phenotype throughout the 
time course of study. In contrast, under identical seeding 
densities (1 . 104/cm2), FGF-l- but not Bg-transduced 
cells adopted a transformed cellular phenotype (Fig. 4C), 
characterized by focal growth patterns and a spindle-like 
morphology, when maintained (72 h) in reduced serum 
(OS%, v/v). This observation is consistent with previous 
transfection studies using FGF chimeras containing various 
signal sequences [l&21] which have described the ability 
of secreted FGF-1 to mediate cellular transformation. In 
addition, daily feeding fresh media (0.5%, v/v, FBS) to 
the FGF-l-transduced cells retarded their growth rate and 
prevented the appearance of the transformed phenotype. 
Bg-transduced cells adopted this characteristic transformed 
phenotype when treated daily for 3 days with recombinant 
FGF-1 (50 ng/ml) alone or in combination with heparin 
(20 USP units/ml). The morphological response to these 
daily treatments was dependent on constant presentation of 
the growth factor since its elimination resulted in reversion 
to a normal phenotype. 
Induction of cellular transformation by recombinant 
FGF-1 treatments and antibody inhibition (Fig. 3A) of the 
proliferation index of FGF- 1 -transduced cells suggested 
the potential involvement of this growth factor during 
phenotypic changes induced by serum-starvation. Conse- 
quently, in situ immunohistochemical methods were used 
to evaluate expression of FGF-1 in individual transduc- 
tants. Under normal culture conditions (lo%, v/v, FBS), 
Fig. 5. In situ immunohistochemical analysis of transduced cells. Sub-confluent populations of FGF-l-(panels A, C and D) and (hst/KS) FGF-I- [211 
(panel B) transduced cells were maintained (72 h) in either 10% (v/v) FBS (panels A and B) or 0.5% (v/v) FBS (panels C and D). Cytospin preparations 
of transduced cells were analyzed by immunohistochemical techniques using the affinity-purified polyclonal antibody specific for FGF-I 1501 and 
localization of the growth factor was visualized (brown staining) by light microscopy (240 X magnification). Note absence of nuclear-associated staining 
in FGF-l-transduced cells maintained (72 h) in 0.5%, v/v, FBS containing daily additions (0, 24, 48 h) of 30 pg/ml polyclonal anti-FGF-1 antibody 
(panel D). 
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FGF- 1 -transduced cells readily demonstrated increased im- 
munoreactivity for FGF- 1. Staining was distributed largely 
within the cytoplasmic compartment with occasional ar- 
rays confined to the plasma membrane (Fig. 5A). In 
contrast, FGF- l-transduced cells maintained in reduced 
serum (0.5%, v/v, FBS) displayed immunoreactivity for 
FGF-1, not only distributed within the cytosol but also 
associated with the nuclear compartment in 28.9% of the 
total cell population (Fig. 5C). Daily additions of antibody 
against the polypeptide growth factor significantly (P < 
0.001) inhibited the appearance of immunoreactivity (< 
5.2% total cells) associated with the nucleus (Fig. 5D). As 
a positive control, cells transduced with a secreted, chimeric 
form of FGF-1, exhibited immunoreactivity for FGF-1 
localized predominantly in the nuclear compartment of 
greater than 95% of the cell population (Fig. 5B). 
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Biochemical analyses also were performed on individ- 
ual cell populations under defined culture conditions. 
Western blot analysis demonstrated that minimal levels 
(approximately 4 ng/ lo6 cells) of affinity-extracted, im- 
munoreactive protein (17 kDa) were present in total cellu- 
lar extracts from both transduced cell populations suggest- 
ing that embryonic fibroblasts express low, but detectable 
levels of the full length, endogenous murine FGF-1 (Fig. 
6A-C, lane 2). Expression of the truncated FGF-1 trans- 
gene (Fig. 6B and C, lane 2) was limited to FGF-l-trans- 
duced cells, which demonstrated steady-state levels of the 
intracellular growth factor (approximately 40-80 ng/ lo6 
cells) that were unaffected by culture conditions (lo%, 
v/v, or 0.5%, v/v, FBS). Preincubation (16 h, 4°C) of the 
antibody with 1 00-fold molar excess of recombinant FGF- 1 
completely blocked Western blot staining. In addition, 
Western analysis of total, unfractionated cell extracts failed 
to detect the presence of any immunoreactive bands. It 
should be noted, that in our experience, techniques of 
PAGE and efficient electrophoretic transfer are limited to 
50-100 pg of total protein per loading. This value repre- 
sents less than 1 . 10” total cell extract which represents a 
level of the FGF-1 transgene below 8 ng, a value repre- 
senting the lower limits of detection by the Western tech- 
niques used in this study. Consequently, affinity-extraction 
(heparin-Sepharose) techniques permitted the opportunity 
to analyze FGF-1 proteins in a more rational manner. 
Fig. 6. Localization of FGF-I protein by individual transductants under 
defined culture conditions. All of the affinity-extracted proteins, har- 
vested from either the total cellular extract (lane 2) or fractionated nuclei 
(lane 3), were resolved by reducing 15% (w/v) SDS-PAGE (lanes l-4). 
Affinity-extracted proteins recovered from conditioned media were treated 
in the absence (lane 6) or presence (lane 7) of 10 mM D’lT prior to 
fractionization by non-reducing 15% (w/v) PAGE, in which the presence 
of SDS (2%, w/v) was restricted to the sample buffer. Gels were 
evaluated by Western analysis using an affinity-purified polyclonal anti- 
body specific for FGF-I. (Panel A) Bg-transduced cells (5. 106) main- 
tained in 10% (v/v) FBS, 72 h. (Panels B and C) FGF-l-transduced cells 
(1. 106) maintained (72 h) in either 10% (v/v) or 0.5% (v/v) FBS, 
respectively. Recombinant FGF-12,.,s4 (0.3 pg; lanes 1 and 5) and full 
length FGF-1 ,_,51 (0.4 pg; lanes 4 and 8) served as controls. Approxi- 
mate sizes (kDa) were estimated using molecular mass standards (right). 
cells maintained in reduced serum (0.5%, v/v, FBS, 72 h). 
These results complement in situ immunohistochemical 
analysis (Fig. 5) and predict the extracellular appearance of 
FGF-1, since nuclear localization involves an exogenous 
pathway [26]. 
The truncated FGF- 1 transgene, affinity-extracted from Western analysis of concentrated media (10% or 0.5%, 
the total intracellular compartment of FGF- I -transduced v/v, FBS) alone or conditioned (72 h) by Bg-transduced 
cells, displayed mitogenic behavior in the DNA synthesis cells failed to demonstrate the presence of extracellular 
assay similar to that obtained with recombinant FGF-1 FGF- 1, even when affinity-extracted with heparin-sep- 
isolated from E. coli (Fig. 3B). Pretreatment of both these harose (Fig. 6A). In contrast, FGF- 1 -transduced cells main- 
growth factor preparations with the antibody against FGF-1 tained (72 hl in reduced serum demonstrated the extracel- 
significantly (P < 0.00 1) inhibited their mitogenic poten- lular presence of immunoreactive FGF- 1 migrating primar- 
tial. Correlation of this biological data with immunoblot ily as multiple high molecular mass bands, which were 
analysis determined that the intracellular form of FGF-1 resolvable by limited SDS-PAGE immunoblot analysis and 
retained greater than 90% of its mitogenic potential. The included a large percentage of material displaying an 
presence of the affinity-extracted, truncated FGF- 1 trans- apparent molecular mass of approx. 32 kDa (Fig. 6B and 
gene (approximately 20-30 ng/106 cells) in nuclear ex- C, lane 6). Pretreatment of the affinity-purified antibody 
tracts (Fig. 6, lane 3) was restricted to FGF-l-transduced with recombinant FGF-I (loo-fold molar excess) pre- 
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Fig. 7. Kinetics of FGF-1 secretion in response to serum-starvation. 
Affinity-extracted proteins recovered from media conditioned by FGF-I- 
transduced cells (1. 106) were fractionated by non-reducing 15% (w/v) 
Limited SDS-PAGE and evaluated by Western analysis using a poly- 
clonal antibody specific for FGF-1. (Panel A) The extracellular appear- 
ance of immunoreactive FGF-I was analyzed as a function of time in 
culture. Lanes 2, 3, 4, 5 and 6 correspond to proteins recovered following 
24, 48, 60, 72 and 84 h, respectively, of exposure to 0.5% (v/v) FBS. 
(Panel B) The extracellular appearance of immunoreactive FCF-1 was 
analyzed as a function of serum concentration in the culture media. Lanes 
2, 3, 4, 5 and 6 correspond to proteins recovered from FGF- I -transduced 
cells maintained (72 h) in 10, 5, 2, 0.5 and 0.2% (v/v) FBS, respectively. 
Recombinant FGF-l~,_,54 (0.3 pg; lane I, A and 8) and FGF-I,~,,, (0.4 
kg; lane 7, A and B) served as controls. Approximate sizes (kDa) were 
estimated using molecular mass standards (right) 
A 
12 3 MW(Kd) 
B 
vented the appearance of immunoreactive bands, thereby 
confirming both specificity of the antibody probe and 
identity of the high molecular mass bands. Interestingly, 
the appearance of monomeric FGF-1 (16 kDa) was not 
detected in media conditioned by FGF- 1 -transduced cells, 
regardless of specific culture conditions. 
Treatment of the heparin-extracted, high molecular mass 
FGF- 1 complexes with the reducing agent DTT (1 mM) 
and heat (90°C 10 min) generated the appearance of 
FGF-1 migrating as a single band with a representative 
molecular mass (Fig. 6B and C, lane 7). When compared 
to growth in 10% (v/v) FBS, FGF-l-transduced cells 
demonstrated a lo-15-fold increase in extracellular levels 
of the high molecular mass FGF-I complexes when main- 
tained (72 h) in reduced serum (O._~%,V/V, FBS). The high 
molecular mass, complexed forms of FGF-1, affinity-ex- 
tracted from reduced-serum media conditioned (72 h) by 
FGF- l-transduced cells, failed to demonstrate mitogenic 
behavior in the DNA synthesis assay (Fig. 3B). However, 
reduction (1 mM DTT) of the heparin-extracted, high 
molecular mass FGF-1 complexes activated its mitogenic 
potential, an observation that was inhibited significantly 
(P < 0.001) by pretreatment with the polyclonal antibody 
against FGF- 1. Semi-quantitative correlation of this biolog- 
ical data with immunoblot analysis determined that, when 
compared to recombinant FGF-1, the extracellular form of 
FGF-1 retained greater than 90% of its latent mitogenic 
potential. 
A more detailed kinetic analysis (Fig. 7A) of media 
conditioned by FGF- l-transduced cells demonstrated that 
under conditions of serum starvation (0.5%, v/v, FBS), 
high molecular mass complexed forms of extracellular 
FGF-I could be detected within 24 h of culture. No 
immunoreactive FGF-1 was detected in the conditioned 
media after 4,8, or 16 h of exposure to 0.5% (v/v) FBS. 
After 24 h, the amount of complexed FGF-1 released from 
FGF-l-transduced cells increased as a function of time, 
1 2 3 4 MW(Kd) 
C 
1 2 MWO 
-214 
-111 
-74 
Fig. 8. Autocrine/paracrine stimulation of tyrosine phosphorylation. Individual cell extracts were immunoprecipitated with a monoclonal anti-phospho- 
tyrosine antibody, resolved by either 88, w/v (A and B) or 12%. w/v (C) reducing SDS-PAGE, and Western analyzed with polyclonal antibodies against 
either phosphotyrosine (A and B) or c-src (C). (Panel A) Total endogenous cellular extract immunoprecipitated from FGF-l-transduced cells (1 106) 
maintained (72 h) in either serum-free, hormonally defined media (lane I), 0.5% (w/v) FBS (lane 2) or 10% (w/v) FBS (lane 3). (Panel B) Total cellular 
extracts immunoprecipitated from quiescent Bg-transduced cells (5 106) following treatment (37°C 60 min) with media (0.5% (v/v) FBS) conditioned 
(72 h) by 1 lo6 Bg-transduced cells (lane I), untreated (lane 2) or treated (1 mM DTT, lane 3) media conditioned for 72 h (0.5% (v/v) FBS) by 1 10’ 
FGF-l-transduced cells, or heparin (20 U/ml) and 10 ng/ml recombinant FGF-12,.,,, (lane 4). (Panel C) Total endogenous cellular extract 
immunoprecipitated from FGF-l-transduced cells (1 . 106) maintained (72 h) in either lo%, v/v (lane 1) or 0.5% (V/V) FBS (lane 2). Arrowheads (left) 
identify responding phosphotyrosyl polypeptides, whose approximate sizes (kDa) were estimated using prestained molecular mass standards (right). 
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wherein maximal levels were achieved within 60 h and 
persisted throughout the time course of study (84 h). 
Additional efforts included Western analysis of heparin-ex- 
tracted media conditioned by FGF- 1 -transduced cells 
maintained for 72 h in different concentrations of serum 
(Fig. 7B). These results demonstrate that the extracellular 
appearance of the FGF-1 complexes is inversely related to 
the concentration of serum in the culture media, wherein 
maximum levels were observed in 0.5% (v/v) and 
O.~%(V/V) FBS (Fig. 7B, lanes 5 and 6, respectively). 
Limited SDS-PAGE analysis failed to demonstrate the 
presence of extracellular, immunoreactive FGF-1 as a na- 
tive structure during these kinetic studies. 
To validate further the biological potential of extracellu- 
lar FGF- 1, endogenous levels of tyrosine phosphorylation 
were examined in FGF-l-transduced cells maintained (72 
h) under defined culture conditions (Fig. 8A). When com- 
pared to cells quiesced in serum-free, hormonally defined 
media, FGF-l-transduced cells grown in complete media 
(IO%, v/v, FBS) demonstrated a slight increase in tyro- 
sine phosphorylation levels (Fig. 8A, lane 3). In contrast, 
FGF- l-transduced cells that were maintained in reduced 
serum (0.5% FBS, v/v) demonstrated an exaggerated 
tyrosine phosphorylation of polypeptides with apparent 
molecular masses of 150, 130 and 90 kDa (Fig. 8A, lane 
2). Also, when compared to cells maintained in lO%(v/v) 
FBS, increased phosphorylation of endogenous c-src, mi- 
grating with an apparent molecular mass of approx. 60 
kDa, was evident in FGF-l-transduced cells maintained 
(72 h) in reduced (0.5%, v/v, FBS) serum (Fig. 8C). 
Increased tyrosine phosphorylation of endogenous cor- 
tactin, a substrate for C-SK [51], also was observed as a 
consequence of culturing FGF-l-transduced cells in re- 
duced serum (not shown). In addition, reduced-serum me- 
dia conditioned (72 h) by FGF- 1 -transduced cells induced 
FGF-specific tyrosine phosphorylation in quiescent Bg- 
transduced cells (Fig. 8B, lane 2), an observation that was 
exaggerated by pretreatment of the conditioned media with 
DTT (Fig. 8B, lane 31. Similar results were obtained 
following pretreatment of this conditioned media with 
N-acetyl cysteine and reduced, but not oxidized, glu- 
tathione (not shown). Phosphorylation of tyrosine residues 
on polypeptides with apparent molecular masses of 150, 
130 and 90 kDa (Fig. 8B, lane 4) is consistent with those 
substrates responding to exogenous recombinant FGF- 1 
[22,23] and correlates with the requirement for the pres- 
ence of reducing agents to activate the mitogenic potential 
(Fig. 3B) of latent, extracellular FGF-1 released from 
FGF- 1 -transduced cells in response to serum deprivation. 
4. Discussion 
A wide variety of diploid cells either in vitro or in vivo 
both express and respond to FGF-1, a prototypic member 
of the FGF family of polypeptide growth factors that does 
not contain a classical signal peptide sequence for secre- 
tion. This feature alone suggests conserved evolutionary 
pressure against the extracellular presentation of this growth 
factor, which would complete an autocrine/paracrine loop 
leading to inopportune biological consequences. Evidence 
of this potential has been demonstrated in vivo wherein the 
delivery of a single dose of exogenous FGF-1 induced 
site-specific angiogenesis and neurogenesis in adult ani- 
mals [52,53]. Similar results have been obtained in porcine 
arteries following introduction of a DNA vector orchestrat- 
ing expression of a secreted form of FGF-1 [54]. In 
addition, the ability of FGF-1 to disrupt the normal pattern 
of lens differentiation in transgenic mice is restricted to the 
extracellular presentation of this polypeptide growth factor 
[55]. Consequently, mechanisms whereby FGF- 1 gains 
access to the extracellular compartment are requisite to 
understanding the involvement of this mitogen in patho- 
physiological situations, normal physiologic repair mecha- 
nisms, and regulation of development. 
Most diploid cells in vitro, including primary embry- 
onic murine fibroblasts, express relatively low levels of 
endogenous FGF-1, suggesting that large scale cell culture 
would be required to study trafficking and compartmental- 
ization of the growth factor. To overcome this limitation, 
retroviral vectors were designed to deliver a single copy of 
the human cDNA sequence, which would direct constitu- 
tive overexpression of intracellular FGF- 1 as a biologically 
active protein and thereby permit evaluation of growth 
factor partitioning in normal diploid fibroblasts under de- 
fined, small-scale culture conditions. The truncated form 
of the growth factor was chosen both to allow discrimina- 
tion between the full length of endogenous murine and the 
transduced human gene product and to prevent potential 
translation problems previously encountered in E. coli 
[39]. As an extracellular protein, this form of FGF-1 has 
been demonstrated to retain full biological activity both in 
vitro [39] and in vivo [52-551. Results presented here are 
consistent with these observations and further suggest that 
deletion of the first 21 amino acids from the NH,-terminus 
generates a form of the growth factor that retains full 
biological activity including structural features related to 
heparin and receptor binding [56], nuclear localization [25], 
cytosolic retention [33], and extracellular release as a 
function of biological stress [32,33]. 
Several features of the experimental model used in this 
study provide insight into the physiological consequences 
of intrinsic FGF-1 expression beyond that previously re- 
ported in transfection experiments, which have docu- 
mented the ability of intrinsic FGF-1 to mediate cellular 
transformation in established cell lines [ 18-201. In contrast 
to these studies, primary murine fibroblasts constitutively 
expressing FGF-1 under normal culture conditions main- 
tained both a representative cellular phenotype and an 
anchorage-dependency for growth. It is suggested that, 
compared to transfected established cell lines, transduced 
primary cultures of normal cells reflect a situation more 
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reminiscent of the in vivo environment by maintaining 
stringent control over growth promoting processes, includ- 
ing mechanisms that regulate the retention, secretion and 
biological consequences of intracellular FGF- I. High titer 
supernatants generated transduction efficiencies that per- 
mitted immediate isolation (FACS), expansion, and bio- 
chemical analyses of transduced primary cells, which were 
subjected to minimal population doublings and non-stress- 
ful culture densities. Less efficient transfection experi- 
ments typically require cells to survive both long-term 
selection in culture and growth under stressful, low density 
conditions. Consequently, abberant phenotypic appearance 
and growth behavior in vitro of cell lines transfected with 
intrinsic FGF-1 would be consistent with the release of the 
growth factor from cells in response to biological stress 
[321. 
Initial evidence of an extracellular pathway for release 
of FGF- 1 included the observation that FGF- 1 -transduced 
cells maintained in normal culture conditions (IO%, v/v, 
FBS) demonstrated a slight growth advantage when com- 
pared to control-transduced cells. Under optimal conditions 
of growth, FGF-l-transduced cells also exhibited a slight 
increase of endogenous FGF-specific tyrosine phospho- 
rylation which correlated with low, but detectable levels of 
extracellular FGF-1. Interestingly, the use of a novel im- 
munoblot assay was able to detect the secreted form of 
FGF- 1 as multiple, high molecular mass complexes, which 
were readily dissociated with reducing agents to a single 
species of representative molecular mass. Under normal 
culture conditions, FGF- 1 was not detected as a nuclear-as- 
sociated protein in FGF- 1 -transduced cells; however, this 
may reflect the sensitivity limits of both the immunoblot 
and the in situ techniques used in these studies. Collec- 
tively, these results suggest that FGF- 1 -transduced primary 
murine fibroblasts contain an autocrine/paracrine loop 
operating at either a reduced or minimal level under 
conditions requisite for cell growth. 
In contrast to cells constitutively expressing intrinsic 
FGF- 1 under normal culture conditions, FGF- 1 -transduced 
cells maintained in reduced serum demonstrated: (i) an 
increased growth advantage with delayed kinetics, (ii) 
retention of a high proliferation index that was inhibited by 
inclusion of the anti-FGF-1 antibody in the culture media, 
(iii) a change in cellular morphology to a more trans- 
formed phenotype, (iv) the appearance of immunoreactive 
FGF-1 associated with the nuclear compartment by a 
process inhibited by extracellular antibody against FGF- I, 
and (v) an increase of endogenous FGF-specific tyrosine 
phosphorylation. Collectively, these observations predict 
the induction of an FGF- 1 extracellular autocrine/paracrine 
loop in response to serum deprivation. As an isolated 
result, increased levels of endogenous tyrosine phospho- 
rylation do not rule out the potential existence of other 
polypeptide factors in the conditioned media which may 
stimulate converging signal transduction cascades. How- 
ever, under conditions of serum deprivation, we have not 
identified the extracellular appearance of FGF-2, which 
has been demonstrated to be secreted from cytoplasmic 
stores by a nonconventional pathway [31]. The mitogenic 
potential of FGF-1 involves nuclear association of the 
polypeptide by an extracellular pathway that can occur 
either through high affinity receptors and associated signal 
transduction events [26] or by transport of the polypeptide 
into the cell in the absence of tyrosine phorphorylation 
[57]. Results here are consistent with the former mecha- 
nism, wherein serum starvation induced both nuclear asso- 
ciation of FGF-1 and FGF-specific tyrosine phosphoryla- 
tion, including increased phosphorylation of the FGF re- 
ceptor- 1 substrate, c-src [5 I] and cortactin, a substrate for 
c-src which responds to exogenous FGF-1 [58]. Conse- 
quently, it seemed reasonable to anticipate the appearance 
of the growth factor in reduced-serum media conditioned 
by FGF-l-transduced cells. Indeed, when compared to 
normal culture conditions, FGF- 1 -transduced cells exposed 
to reduced serum demonstrated release of increased levels 
of the multiple, high molecular mass complexes, which 
were readily dissociated to a biologically active, native 
form of FGF-1 by treatment with DTT. This observation 
suggests that serum-starvation induced a nonconventional 
pathway for secretion of FGF-1, an interpretation which is 
consistent with that observed during temperature-induced 
[32,33] release of the growth factor. 
The kinetics of the extracellular appearance of FGF- 1 in 
response to serum deprivation were evaluated to charac- 
terize the secretory process in vitro. The cellular release of 
FGF-1 complexes was inversely related to serum concen- 
tration with maximum levels of secretion requiring greater 
than 48 h exposure to 0.5% (v/v) FBS. The growth 
potential, proliferation index, appearance of a transformed 
phenotype, induction of FGF-specific phosphorylation, and 
nuclear association of FGF-1 correlated with the kinetics 
of FGF-1 secretion. Differential levels of gene expression 
did not contribute to either the delayed kinetics or the 
overall levels of growth factor secretion since similar 
levels of FGF-1 mRNA and protein were observed in the 
FGF-l-transduced cells maintained in either 10% (v/v) or 
0.5% (v/v) FBS. Assessment of both LDH release and 
FDA-PI staining suggested that sublethal cell injury did 
not contribute to the release of FGF-1. In fact, when 
compared to Bg-transduced cells, serum-deprived popula- 
tions of FGF- 1 -transduced cells demonstrated significantly 
reduced levels of cell death/damage. This observation 
alone suggests the induction of a biological mechanism to 
promote cell survival. 
Whereas the exact identity of the extracellular, high 
molecular mass FGF-1 complexes are not known, our data 
are consistent with the recent observations that FGF-1 is 
released in response to heat shock [32] and HIV-l TAT 
protein [21] as a biologically inactive homodimer. Indeed, 
the major species detected in our immunoblot assay corre- 
sponds well with the reported molecular mass representa- 
tive of the FGF-1 homodimer induced by copper oxidation 
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[59]. As a homodimer structure, FGF-1 is biologically 
inactive and requires reduction of oxidized cysteine 
residues to restore complete heparin affinity, receptor bind- 
ing and full mitogenic potential [59]. The ability of reduc- 
ing agents to both dissociate the secreted FGF-1 com- 
plexes, activate the full mitogenic potential of extracellular 
FGF-1, and exaggerate paracrine stimulation of FGF- 
specific tyrosine phosphorylation is consistent with these 
results. Collectively, these observations, coupled with the 
involvement of FGF-1 cysteine residues during tempera- 
ture-induced release of the growth factor 1331, suggest a 
common FGF-1 secretory pathway. While the exact bio- 
logical mechanisms responsible for formation and activa- 
tion of the secreted FGF-1 complex are not known, we 
suggest that localized redox potential may be involved, 
particularly since oxidative and hypothermic stress re- 
sponses overlap [34]. The observation that continuous 
(daily) feeding of FGF-1 transduced cells prevented the 
induction of FGF- 1 specific receptor-mediated cellular re- 
sponses is consistent with this concept, since the process 
will not only remove extracellular FGF-1 complexes but 
also restore intracellular and extracellular redox potentials 
[60]. Results presented here suggest further that media 
conditioned by FGF-I transduced cells contain an appro- 
priate mechanism to activate some of the latent FGF-1 
complexes, thereby permitting completion of an extracellu- 
lar autocrine/paracrine loop. The absence of detectable 
steady state levels of extracellular FGF-1 as a native 
structure, the appearance of characteristics associated with 
exogenous FGF-1 treatment, and the observation that na- 
tive FGF-1 requires only partial receptor ocuupancy to 
initiate DNA synthesis in vitro [52] would be consistent 
with this interpretation. However, the rate of complex 
activation (reduction) appears to be reduced compared to 
that of formation/secretion as evidenced by the accumula- 
tion of high molecular mass FGF-1 species and the ob- 
served delayed kinetics associated with growth in reduced 
serum. 
An underlying implication of our studies with serum 
deprivation, a situation more reflective of the in vivo 
environment, suggests that the nonconventional pathway 
for FGF- 1 secretion occurs at a reduced level under normal 
physiologic conditions. This feature would confirm a po- 
tential mechanism whereby reducing agents may act as 
nutrients to promote low density cell growth in vitro [61] 
and provide biological insight into the process whereby 
FGF-1 functions as a survival factor [62]. Increased growth 
factor secretion observed in cells constitutively expressing 
high levels of FGF-1 mRNA would be consistent with the 
suggestion that regulation of this nonconventional pathway 
is controlled by levels of newly translated polypeptide 
rather than by activation of cytosolic stores [33]. It remains 
to be determined whether secretion and activation of latent 
FGF- I complexes are involved during in vivo pathophysio- 
logic conditions, such as atherosclerosis [63] and kidney 
injury [64], which have been demonstrated to include 
increased transcription of FGF-1 mRNA. 
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